UC San Diego Health now offers new treatment option for people with refractory epilepsy

UC San Diego Health now offers patients with epilepsy another non-pharmacological way to treat seizures. For the more than one million individuals who live with uncontrolled seizures despite taking medications, UC San Diego Health recently began offering the first and only FDA-approved brain-responsive neurostimulation (RNS) system designed for the treatment of refractory epilepsy.

"This device is approved for use in patients who have seizures coming from up to two different locations in the brain," said Jerry J. Shih, MD, epileptologist and director of the Comprehensive Epilepsy Center at UC San Diego Health. "When unusual brain activity is detected, the neurostimulation device sends brief painless electrical pulses with the goal of disrupting the emerging seizure and to normalize brain waves."

Shih added, "This device provides another treatment option for patients who were previously not candidates for traditional surgery because the seizure focus was in or near important brain structures controlling memory, language or movement."

"In clinical trials, patients treated with this device experienced substantial seizure reductions in the first year that continued to improve over time," said Sharona Ben-Haim, MD, neurosurgeon at UC San Diego Health. "The device continuously monitors and detects the patient's unique brain activity, allowing us to personalize treatment for each individual."

Epilepsy is a neurological condition in which patients experience seizures, sudden surges of electrical activity in the brain. Symptoms range from brief staring spells to uncontrollable limb movements. About one in 26 people in the United States will develop a seizure disorder. Treatment with medications can control seizures for 60 to 65 percent of patients, but 35 to 40 percent of patients continue to have seizures, affecting their quality of life.

Called the RNS System, the device is the first and only closed-loop, brain-responsive neuromodulation system. The neurostimulation system consists of a small, implantable neurostimulator connected to leads (tiny wires) that are placed in up to two seizure onset areas. The system comes with a remote monitor that patients use at home to wirelessly collect information from the neurostimulator and then transfer it to a patient data management system.

The patient's neurologist can log into this system at any time to review accurate, ongoing information about the patient's seizure activity and treatment progress. This helps physicians learn more about their patients' seizures and improves patient care.

The RNS System was developed by NeuroPace, Inc. in Mountain View, CA. The system was approved by the FDA in November 2013. More than 1,300 patients have received the device nationally.

The Comprehensive Epilepsy Center at the UC San Diego Health Neurological Institute is the only nationally designated Level 4 Epilepsy Center in the region. It offers the latest technological advances in diagnostics, medical therapies, surgical procedures and clinical trials.

The epilepsy team includes epileptologists, neuropsychologists, neuroradiologists, epilepsy neurosurgeons, EEG technologists, clinical nurse specialists, and researchers.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New blood test could help identify patients at risk for cognitive impairment